Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer.
Saved in:
| Title: | Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer. |
|---|---|
| Authors: | Chen WY; Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, 11031, Taiwan.; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan., Huang KH; Department of Surgery, Division of Urology, Chi-Mei Medical Center, Tainan, 710, Taiwan., Kajla G; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Wen YC; Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, 11031, Taiwan.; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.; TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei, 11031, Taiwan., Liu MK; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Fan YC; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Dung PVT; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Yeh HL; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Chen WH; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Jiang KC; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Li HR; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan., Chen CS; School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan., Huang J; Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA., Beltran H; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02215-5450, USA., Liu YN; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan. liuy@tmu.edu.tw.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan. liuy@tmu.edu.tw.; Prostate Center of Excellence, Taipei Medical University Hospital, Taipei Medical University, Taipei, 11031, Taiwan. liuy@tmu.edu.tw.; Taipei Medical University, 301, Yuantong Road, Zhonghe District, New Taipei City, 234, Taiwan. liuy@tmu.edu.tw. |
| Source: | Cell communication and signaling : CCS [Cell Commun Signal] 2026 Jun 08. Date of Electronic Publication: 2026 Jun 08. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101170464 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-811X (Electronic) Linking ISSN: 1478811X NLM ISO Abbreviation: Cell Commun Signal Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42252434 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Chen+WY%22">Chen WY</searchLink>; Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, 11031, Taiwan.; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.<br /><searchLink fieldCode="AU" term="%22Huang+KH%22">Huang KH</searchLink>; Department of Surgery, Division of Urology, Chi-Mei Medical Center, Tainan, 710, Taiwan.<br /><searchLink fieldCode="AU" term="%22Kajla+G%22">Kajla G</searchLink>; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wen+YC%22">Wen YC</searchLink>; Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, 11031, Taiwan.; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.; TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei, 11031, Taiwan.<br /><searchLink fieldCode="AU" term="%22Liu+MK%22">Liu MK</searchLink>; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan.<br /><searchLink fieldCode="AU" term="%22Fan+YC%22">Fan YC</searchLink>; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan.<br /><searchLink fieldCode="AU" term="%22Dung+PVT%22">Dung PVT</searchLink>; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan.<br /><searchLink fieldCode="AU" term="%22Yeh+HL%22">Yeh HL</searchLink>; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chen+WH%22">Chen WH</searchLink>; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan.<br /><searchLink fieldCode="AU" term="%22Jiang+KC%22">Jiang KC</searchLink>; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan.<br /><searchLink fieldCode="AU" term="%22Li+HR%22">Li HR</searchLink>; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chen+CS%22">Chen CS</searchLink>; School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.<br /><searchLink fieldCode="AU" term="%22Huang+J%22">Huang J</searchLink>; Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.<br /><searchLink fieldCode="AU" term="%22Beltran+H%22">Beltran H</searchLink>; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02215-5450, USA.<br /><searchLink fieldCode="AU" term="%22Liu+YN%22">Liu YN</searchLink>; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan. liuy@tmu.edu.tw.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, New Taipei City, 235, Taiwan. liuy@tmu.edu.tw.; Prostate Center of Excellence, Taipei Medical University Hospital, Taipei Medical University, Taipei, 11031, Taiwan. liuy@tmu.edu.tw.; Taipei Medical University, 301, Yuantong Road, Zhonghe District, New Taipei City, 234, Taiwan. liuy@tmu.edu.tw. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101170464%22">Cell communication and signaling : CCS</searchLink> [Cell Commun Signal] 2026 Jun 08. <i>Date of Electronic Publication: </i>2026 Jun 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101170464 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1478-811X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221478811X%22">1478811X </searchLink><i>NLM ISO Abbreviation: </i>Cell Commun Signal <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42252434 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12964-026-02977-y Languages: – Code: eng Text: English Titles: – TitleFull: Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Chen WY – PersonEntity: Name: NameFull: Huang KH – PersonEntity: Name: NameFull: Kajla G – PersonEntity: Name: NameFull: Wen YC – PersonEntity: Name: NameFull: Liu MK – PersonEntity: Name: NameFull: Fan YC – PersonEntity: Name: NameFull: Dung PVT – PersonEntity: Name: NameFull: Yeh HL – PersonEntity: Name: NameFull: Chen WH – PersonEntity: Name: NameFull: Jiang KC – PersonEntity: Name: NameFull: Li HR – PersonEntity: Name: NameFull: Chen CS – PersonEntity: Name: NameFull: Huang J – PersonEntity: Name: NameFull: Beltran H – PersonEntity: Name: NameFull: Liu YN IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 06 Text: 2026 Jun 08 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1478-811X Titles: – TitleFull: Cell communication and signaling : CCS Type: main |
| ResultId | 1 |